ReviewHealthcare (Basel, Switzerland)2018
Sepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift?
Review in Healthcare (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Dysregulation of Neutrophil-Endothelial Communication in Sepsis: Mechanisms and Therapeutic Perspectives.Cells · 2026Review
- Neutrophil-derived ROS as a rapid functional biomarker: diagnostic and prognostic performance of the Leukocyte ImmunoTest in infection and sepsis.Frontiers in immunology · 2026Observational
- Observational
- Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics.Frontiers in immunology · 2025Article
- Interaction between post-tumor inflammation and vascular smooth muscle cell dysfunction in sepsis-induced cardiomyopathy.Frontiers in immunology · 2025Article
- Neonatal Sepsis: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- Distinct functional neutrophil phenotypes in sepsis patients correlate with disease severity.Frontiers in immunology · 2024Article
- Roquin-1 resolves sepsis-associated acute liver injury by regulating inflammatory profiles via miRNA cargo in extracellular vesicles.iScience · 2023Article
- Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression.Microorganisms · 2023Review
- Distinct subsets of neutrophils crosstalk with cytokines and metabolites in patients with sepsis.iScience · 2023Article
- The critical role of neutrophil-endothelial cell interactions in sepsis: new synergistic approaches employing organ-on-chip, omics, immune cell phenotyping andFrontiers in cellular and infection microbiology · 2023Review
- Investigating the Effects of Hyperbaric Oxygen Treatment in Necrotizing Soft Tissue Infection With Transcriptomics and Machine Learning (the HBOmic Study): Protocol for a Prospective Cohort Study With Data Validation.JMIR research protocols · 2022Article
- Review
- The liver in sepsis: molecular mechanism of liver failure and their potential for clinical translation.Molecular medicine (Cambridge, Mass.) · 2022Review
- Omics of endothelial cell dysfunction in sepsis.Vascular biology (Bristol, England) · 2022Review
- The Landscape of Featured Metabolism-Related Genes and Imbalanced Immune Cell Subsets in Sepsis.Frontiers in genetics · 2022Article
- Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research.Pediatric research · 2022Review
- Resolving trained immunity with systems biology.European journal of immunology · 2021Review
- Challenges in developing a consensus definition of neonatal sepsis.Pediatric research · 2020Review
- SEPSIS. Educational and Best Practice Frontiers. Beyond the Boundaries of Fatality, Enhancing Clinical Skills and Precision Medicine.Therapeutics and clinical risk management · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis has over the years proven a considerable challenge to physicians and researchers. Numerous pharmacological and non-pharmacological interventions have been tested in trials, but have unfortunately failed to improve the general prognosis. This has led to the speculation that the sepsis population may be too heterogeneous to be targeted with the traditional one treatment suits all' approach. Recent advances in genetic and biochemical analyses now allow genotyping and biochemical characterisation of large groups of patients via the 'omics' technologies. These new opportunities could lead to a paradigm shift in the approach to sepsis towards personalised treatments with interventions targeted towards specific pathophysiological mechanisms activated in the patient. In this article, we review the potentials and pitfalls of using new advanced technologies to deepen our understanding of the clinical syndrome of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.